RUNX2 (located at 6p21) regulates the expression of genes related to pDC differentiation and migration, and enables BPDCN cell survival and proliferation.[38] The pDC-specific RUNX2 super enhancer was hijacked, which not only promotes RUNX2 expression, but also activates MYC transcription, which promotes the occurrence and development of BPDCN.[37] In addition, MYB and MLL rearrangement are also observed in BPDCN, and MYB may be a major driver of BPDCN in children.[39–41]. The gene discussed is RUNX2; the disease is CD4+/CD56+ hematodermic neoplasm.